Drug Trial Radar · NCT06293365
Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
155
Actual
Start
Jul 2, 2024
Primary completion
Feb 17, 2026
Study completion Jan 16, 2029
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate the comparability of ianalumab exposure following the sub-cutaneous (s.c.) administration of one injection of 300 mg/2 mL auto-injector (AI) versus two injections of 150 mg/1 mL pre-filled syringe (PFS), and to evaluate the safety and tolerability of ianalumab following the s.c. administration of both devices in participants with rheumatoid arthritis (RA), Sjögren's disease (SjD), or systemic lupus erythematosus (SLE). A second cohort will be included with the objective of demonstrating the comparability of pharmacokinetics of ianalumab between 1 x 2 mL Pre-filled Syringe (PFS) and 2 x 1 mL PFS.
Conditions
- Sjögrens Disease
- Systemic Lupus Erythematosus
- Rheumatoid Arthritis
Interventions
VAY736 1ml PFSBiological
Solution for injection.
VAY736 2 ml PFSBiological
Solution for injection
VAY736 2ml AIBiological
Solution for injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1: Area under the curve (AUC) calculated to the end of a dosing interval (tau) at steady-state (AUCtau) for ianalumabTime frame: Over a dosing interval after 3rd (between Week 8 and 12) and 6th dose (between Week 20 and 24).
- Cohort 1: Maximum (peak) observed serum drug concentration after dose administration (Cmax) for ianalumabTime frame: Over a dosing interval after 3rd (between Week 8 and 12) and 6th dose (between Week 20 and 24).
- Cohort 2: Area under the curve (AUC) calculated to the end of a dosing interval (tau) at steady-state (AUCtau) for ianalumabTime frame: Over a dosing interval after 3rd (between Week 8 and 12) and 6th dose (between Week 20 and 24).
- Cohort 2: Maximum (peak) observed serum drug concentration after dose administration (Cmax) for ianalumabTime frame: Over a dosing interval after 3rd (between Week 8 and 12) and 6th dose (between Week 20 and 24).
Locations
37 sites in 8 countries. Site status is shown where the registry gives one.
Pinnacle Research Group Llc
Anniston, Alabama
Providence Medical Foundation
Fullerton, California
Advanced Medical Research
La Palma, California
Conquest Research
Winter Park, Florida
Parris and Associates Rheumatology
Lawrenceville, Georgia
Indiana Univ School of Dentistry
Indianapolis, Indiana
Ochsner Health System
Baton Rouge, Louisiana
Ahmed Arif Medical Research Center
Grand Blanc, Michigan
Paramount Med Rsrch and Consult LLC
Middleburg Heights, Ohio
RAO Research LLC
Oklahoma City, Oklahoma
Altoona Center for Clin Res
Duncansville, Pennsylvania
West Tennessee Research Institute
Jackson, Tennessee
Shelby Research LLC
Memphis, Tennessee
Novel Research LLC
Bellaire, Texas
Southwest Rheum Rsrch LLC
Mesquite, Texas
Uni of Texas Health Science Center
San Antonio, Texas
Advanced Rheumatology of Houston
The Woodlands, Texas
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Quilmes, Buenos Aires, Argentina
Novartis Investigative Site
San Miguel Tucuman, Tucumán Province, Argentina
Novartis Investigative Site
Hamilton, Ontario, Canada
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Rimouski, Quebec, Canada
Novartis Investigative Site
Trois-Rivières, Quebec, Canada
Novartis Investigative Site
Brno, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Uherské Hradiště, Czechia
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, Hungary
Novartis Investigative Site
Salerno, SA, Italy
Novartis Investigative Site
Krakow, Poland
Novartis Investigative Site
Lublin, Poland
Novartis Investigative Site
A Coruña, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Santiago Compostela, A Coruna, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.